Cost Comparison of Ablation Versus Antiarrhythmic Drugs As First‐Line Therapy for Atrial Fibrillation: An Economic Evaluation of the RAAFT Pilot Study

Khaykin, Yaariv; Wang, Xiaoyin; Wazni, Oussama; Skanes, Allan C.; Humphries, Karin H.; Kerr, Charles R.; Morillo, Carlos A.

doi:10.1111/j.1540-8167.2008.01303.x

Cited by 62 publications

(37 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The mean number of VT/VF ablations per million population in the ESC countries increased from 9.2 in 2014 to 16.0 in 2015. It was highest in Germany (83 per million population) followed by Finland (30), the Czech Republic (28), and Denmark (26) [5] .…”

Section: Ventricular Tachycardia/ventricular Fibrillationmentioning

confidence: 99%

“…The annual cost of medical therapy ranged from USD 3,600 to USD 4300. The study projected costs of ongoing medical therapy and catheter ablation to equalize at 3.2 to 8.4 years of follow-up [15,16] . Reynolds and his group published a Markov model costeffectiveness analysis of ablation vs pharmacotherapy in a simulated cohort of patients with paroxysmal drug refractory AF projected over 5 years [17] .…”

Section: Cost-effectiveness Of Ablation Based On the Example Of Atriamentioning

confidence: 99%

See 1 more Smart Citation

Socioeconomic aspects of arrhythmias treatment in Poland in comparison with other EU countries- systematic report.

Sierpiński¹,

Gierczyński²,

Sobotka³

et al. 2017

Heart Beat

View full text Add to dashboard Cite

Section: Ventricular Tachycardia/ventricular Fibrillationmentioning

confidence: 99%

Section: Cost-effectiveness Of Ablation Based On the Example Of Atriamentioning

confidence: 99%

Socioeconomic aspects of arrhythmias treatment in Poland in comparison with other EU countries- systematic report.

Sierpiński¹,

Gierczyński²,

Sobotka³

et al. 2017

Heart Beat

View full text Add to dashboard Cite

“…Based on the results of the first RAAFT trial, Khaykin et al 45 evaluated the cost-effectiveness of CA as a first-line therapy for AF. The analysis was conducted from the perspective of a publicly funded healthcare payer, using Canadian healthcare cost estimates.…”

Section: Cost-effectiveness Of Ca As a First-line Therapy For Afmentioning

confidence: 99%

Ablation Versus Drugs: What Is the Best First-Line Therapy for Paroxysmal Atrial Fibrillation?

Biase

2014

Circ: Arrhythmia and Electrophysiology

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, was the ablation technique and duration differed between study centers, it is difficult to precisely evaluate the cost-effectiveness of catheter ablation compared with AADs for AF therapy. The limited information available did not permit a consensus on the cost-effectiveness of catheter ablation for AF (25)(26)(27)(28). Thus, the cost comparison of catheter ablation and AADs requires further investigation in future RCTs.…”

mentioning

confidence: 99%

Effect of catheter ablation versus antiarrhythmic drugs on atrial fibrillation: A meta-analysis of randomized controlled trials

Shi

Heng

Liu

et al. 2015

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. The aim of the present study was to compare the health outcomes of catheter ablation therapy against those of antiarrhythmic drugs (AADs) in the management of atrial fibrillation (AF). The effects of catheter ablation and AADs on a number of parameters were compared, including AF recurrence, all-cause mortality, stroke/transient ischemic attack (TIA) and quality of life (QoL). A systematic literature search of PubMed, Embase and the Cochrane Central Register of Controlled Trials was conducted to obtain relevant randomized controlled trials. The relative risks (RRs) and 95% confidence intervals (CIs) of AF recurrence, all-cause mortality and stroke/TIA between catheter ablation and AADs were subsequently calculated. Weighted mean differences (WMDs) and 95% CIs were used to evaluate the QoL between the two therapy groups. In total, 11 randomized trials, which included 1,763 AF patients, were eligible for the meta-analysis. Overall, the results indicated that catheter ablation produces superior outcomes compared with AADs in reducing AF recurrence (RR, 0.47; 95% CI, 0.38-0.58; P<0.001) and improving the QoL (physical component summary: WMD, 2.23; 95% CI, 0.24-4.21; P= 0.03; mental component summary: WMD, 2.69; 95% CI, 0.04-5.35; P= 0.05). However, no statistically significant difference was identified between the two groups with regard to the incidence of all-cause mortality (RR, 0.87; 95% CI, 0.37-2.06; P= 0.76) and stroke/TIA (RR, 1.83; 95% CI, P=0.20). In summary, catheter ablation was demonstrated to markedly reduce AF recurrence and improve QoL when compared with AAD therapy. However, the incidence rates of all-cause mortality and stroke/TIA were comparable between catheter ablation and AAD therapy.

show abstract

Cost Comparison of Ablation Versus Antiarrhythmic Drugs As First‐Line Therapy for Atrial Fibrillation: An Economic Evaluation of the RAAFT Pilot Study

Abstract: RFA as first-line treatment strategy in patients with symptomatic paroxysmal AF was cost neutral 2 years after the initial procedure compared to AAD.

Cited by 62 publications

References 15 publications

Socioeconomic aspects of arrhythmias treatment in Poland in comparison with other EU countries- systematic report.

Socioeconomic aspects of arrhythmias treatment in Poland in comparison with other EU countries- systematic report.

Ablation Versus Drugs: What Is the Best First-Line Therapy for Paroxysmal Atrial Fibrillation?

Effect of catheter ablation versus antiarrhythmic drugs on atrial fibrillation: A meta-analysis of randomized controlled trials

Contact Info

Product

Resources

About